Association of Systemic Inflammatory Indices with Metabolic Dysfunction–Associated Fatty Liver Disease and Liver Fibrosis
Turkish Journal of Gastroenterology · 2026
DOI: 10.5152/tjg.2026.25656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Gastroenterology, 2026. Verfasst von Qinghua Wei und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Third People's Hospital of Yinzhou District, Ningbo, Zhejiang, People's Republic of China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Liver Cirrhosis, Inflammation, Severity of Illness Index. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Aims: The newly proposed metabolic dysfunction–associated fatty liver disease (MASLD) framework reflects the evolving understanding of fatty liver disease, highlighting the importance of exploring novel risk factors beyond traditional metabolic indicators. This study aimed to examine the associations between systemic inflammatory indices and the prevalence of MASLD and liver fibrosis. Materials and Methods: Data from the 2017 MASLD framework reflects the evolving regression was used to assess associations of systemic inflammatory indices—systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), prognostic nutritional index (PNI), aggregate index of systemic inflammation (AISI), inflammation burden index (IBI), neutrophil-to-lymphocyte ratio, neutrophil-to albumin ratio, and pan-immune-inflammation value (PIV)—with MASLD assessed by controlled attenuation parameter (CAP) and liver fibrosis assessed by liver stiffness measurement (LSM), adjusting for confounders.
Results
Analysis of CAP and MASLD revealed that elevated SII, SIRI, LMR, IBI, and PNI were significantly associated with higher CAP values, reflecting increased hepatic steatosis, while PLR showed a negative association. Regarding LSM and liver fibrosis, higher SIRI, PNI, IBI, and AISI were significantly associated with increased liver stiffness, whereas PLR remained inversely related.
Conclusion
This nationally representative study demonstrates that systemic inflammatory dysregulation is linked to both MASLD and liver fibrosis, with distinct biomarker patterns for steatosis and fibrosis. Cite this article as: Wei Q, Shen N, Chen X, Cai J. Association of systemic inflammatory indices with metabolic dysfunction – associated fatty liver disease and liver fibrosis. Turk J Gastroenterol. Published online February 12, 2026. doi: 10.5152/tjg.2026.25656.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Third People's Hospital of Yinzhou District, Ningbo, Zhejiang, People's Republic of China.
Zitieren
APA
Wei, Q., Shen, N., Chen, X., & Cai, J. (2026). Association of Systemic Inflammatory Indices with Metabolic Dysfunction–Associated Fatty Liver Disease and Liver Fibrosis. Turkish Journal of Gastroenterology. https://doi.org/10.5152/tjg.2026.25656
Vancouver
Wei Q, Shen N, Chen X, Cai J. Association of Systemic Inflammatory Indices with Metabolic Dysfunction–Associated Fatty Liver Disease and Liver Fibrosis. Turkish Journal of Gastroenterology. 2026. doi:10.5152/tjg.2026.25656
BibTeX
@article{Wei2026,
author = {Wei, Qinghua and Shen, Neng and Chen, Xiang and Cai, Jiacheng},
title = {Association of Systemic Inflammatory Indices with Metabolic Dysfunction–Associated Fatty Liver Disease and Liver Fibrosis},
journal = {Turkish Journal of Gastroenterology},
year = {2026},
doi = {10.5152/tjg.2026.25656}
}
EUVIMED